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Probe Name Gene Name Information References 
cg05575921 
cg21161138 
AHRR AHRR mediates dioxin toxicity and is involved in regulation of cell growth and 
differentiation. 
Zudaire E et al. 
The aryl hydrocarbon receptor repressor 
 is a putative tumor suppressor gene in multiple human cancers. 
cg03636183 F2RL3 F2RL3 codes for the thrombin PAR-4 
The function of PAR-4 is not fully clear yet but there is emerging evidence that it might 
be involved in the pathophysiology of several malignant tumors including lung cancer 
Zhang Y et al. 
F2RL3 methylation, lung cancer incidence and mortality. 
cg21566642 
cg01940273 
cg05951221 
  the closest gene is ALPPL2 
ALPPL2 is a protein coding gene whose expression is strongly correlated with that of  
Heme Oxygenase-1 gene (it is expressed in many cancers and promotes growth and 
survival of neoplastic cells) 
Tauber S et al. 
Transcriptome analysis of human cancer reveals 
 a functional role of heme oxygenase-1 in tumor cell adhesion. 
cg06126421   the closest gene is FLOT1  
FLOT1 seems to have a role in non-small cell lung cancer tumorigenesis 
Li H et al.  
Abnormal expression of FLOT1 correlates with 
 tumor progression and poor survival in patients with non-small cell lung cancer. 
cg25305703 CASC21 CASC21 (cancer susceptibility candidate 21) has an oncogenic function Kim T et al.  
Long-range interaction and correlation 
 between MYC enhancer and oncogenic long noncoding RNA CARLo-5 
cg02451831 KIAA0087 KIAA0087 is a RNA Gene, and belongs to non coding RNA class 
currently no evidence of involvement in cancer tumorigenesis 
  
cg04884171 BOLA2 BOLA2 encodes the BolA-like protein 2; this protein is conserved from prokaryotes to 
eukaryotes and seems to be involved in cell proliferation or cell-cycle regulation 
Hunecke D et al. 
MYC-regulated genes involved in liver  
cell dysplasia identified in a transgenic model of liver cancer 
cg03898802 DOPEY2 DOPEY2 is a protein coding gene 
currently no evidence of involvement in cancer tumorigenesis 
  
 
Supplementary Table 1 - Main information about involvement in cancer pathways for the top-ranked CpGs found after the locus-by-locus risk 
analysis in NOWAC data (discovery set).  
 
 
  
 
ca co OR for 1 SD 
cg05575921-
AHRR 
all 125 125 0.37(0.31-0.54) 
time to diagnosis <5 years 84 125 0.20(0.10-0.37) 
time to diagnosis >=5 years 41 125 0.42(0.30-0.56) 
  heterogeneity p=0.021 
cg03636183-
F2RL3 
all 125 125 0.40(0.31-0.56) 
time to diagnosis <5 years 84 125 0.32(0.19-0.54) 
time to diagnosis >=5 years 41 125 0.42(0.30-0.57) 
  heterogeneity p=0.375 
 
 
 
Supplementary Table 2 - Analysis stratified by time to diagnosis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
cohorts 
 
NOWAC MCCS NSHDS EPIC-HEIDELBERG 
number of eligible cases 132 367 245 66 
number of cases  
considered in the analysis* 
125* 367* 234* 63 
 
nested case-control studies 
age at baseline (years) 47 (range: 34 -61) 59 (range: 39 - 70) 55 (range: 29-64)  56 (range: 39-65) 
age at diagnosis (years) 56 (range: 47 - 64) 69 (range: 48 - 80) 64 (range: 42-81)  61 (range: 45-70) 
time from blood 
 draw to diagnosis (years) 
3.88 (range: 0.29 - 7.92) 9.38 (range: 0.01 - 18.67) 9.6 (range: 1.1-17.5) 4.8 (range: 1.1-8.6) 
women (N) 250 276 230 22 
men (N) 0 458 238 104 
 
 
Supplementary Table 3 - Summary of the key characteristics of the study groups.  
 
